XYLO is pioneering neuroplastogens – next-generation therapeutics designed to rewire neural circuits and restore brain function. Combining advanced neuroscience with computational drug discovery, we are developing optimized treatments to revolutionize care for neurological and psychiatric conditions. Our mission is to deliver breakthrough therapies that address critical unmet needs and improve the lives of patients worldwide.
Investors 1
Mentions in press and media 2
| Date | Title | Description |
| 15.09.2026 | Xylo Bio Achieves Clinical-Stage Milestone with XYL-1001, a Highly Selective Neuroplastogen Targeting Major Depressive Disorder | BOSTON, Sept. 15, 2026 /PRNewswire/ -- Xylo Bio, a clinical-stage biotechnology company developing novel neurotherapeutics for psychiatric and neurological disorders, today announced the first participants dosed in its Phase 1 clinical stud... |
| 10.01.2025 | Psylo Rebrands as Xylo, with Key Board Appointments and Breakthrough Pipeline Progress | Announces Major Milestones at the JPM Healthcare Conference
SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Psylo, a leader in neurotherapeutics discovery and development, has officially rebranded as Xylo Bio. This transformation reflects the ... |
Reviews 0
